940
Views
70
CrossRef citations to date
0
Altmetric
Original

A powder made from seeds and shells of a rose‐hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: a randomized, double‐blind, placebo‐controlled clinical trial

, &
Pages 302-308 | Received 19 Aug 2004, Accepted 07 Jan 2005, Published online: 12 Jul 2009
 

Abstract

Objective: The aim of this study was to determine whether a herbal remedy made from a subspecies of rose‐hip (Rosa canina) might reduce symptoms of osteoarthritis and consumption of rescue medication in patients suffering from osteoarthritis.

Methods: Ninety‐four patients with osteoarthritis of the hip or knee were enrolled in a randomized, placebo‐controlled, double‐blind crossover trial. Forty‐seven patients were given 5 g of the herbal remedy daily for a period of 3 months and the remaining patients were given a similar amount of placebo. The group initially treated with placebo was then changed to rose‐hip and vice versa for another 3‐month period. Upon inclusion and after 3 weeks and 3 months of each treatment period, pain, stiffness, disability, and global severity of the disease were scored on a Western Ontario and McMaster Universities (WOMAC) questionnaire. After 3 weeks of treatment, patients, if possible, were allowed to reduce their consumption of ‘rescue medication’. Data were analysed on the basis of intention to treat.

Results: Rose‐hip resulted in a significant reduction in WOMAC pain (p<0.014) as compared to placebo, when testing after 3 weeks of treatment. The consumption of ‘rescue medication’ significantly declined as a result of active treatment (p<0.027). WOMAC disability, stiffness, and global assessment of severity of the disease were not altered by 3 weeks but decreased significantly (p<0.018, p<0.038, and p<0.035, respectively) after 3 months of treatment.

Conclusion: The data suggest that the present herbal remedy can alleviate symptoms of osteoarthritis and reduce the consumption of ‘rescue medication’.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.